Posts by Daniel P. Cahill, MD, PhD
-
New Subtype of Glioblastoma Identified
Massachusetts General Hospital neurooncologists have identified a subgroup of IDH wild-type glioblastomas that have a distinct clinical and molecular profile. The findings may have significant implications for targeted therapy in these patients.
-
New Targeted Glioma Therapy Could Suppress Tumor Growth
Mass General has developed a genotype-targeted therapy for glioma, designed to be given at the tumor site during surgery, and an accompanying rapid diagnostic.
Biography
As a neurosurgeon-scientist, Dr. Cahill's clinical practice is focused on the care of brain tumor patients, improving clinical trials of therapy for these patients, and training neurosurgical residents in the diagnosis and treatment of these cancers.
Dr. Cahill was born and raised in Connecticut, attending Yale College and then moving to Baltimore to Johns Hopkins Medical School, receiving his MD/PhD degrees in 2001. His PhD was in Human Genetics, in the laboratory of Drs. Ken Kinzler and Bert Vogelstein. He then completed neurosurgery residency training at Mass General, and was a postdoctoral fellow in the laboratory of Dr. David Louis of Pathology. After completion of his clinical training, he joined the junior faculty in Neurosurgery at MD Anderson Cancer Center in Houston. He later re-joined the faculty of the Mass General Brain Tumor Center in 2011, where he is currently in active practice. He sees patients in the Yawkey Center for Outpatient Care, and his research laboratory is located in the Simches Research Building Brain Tumor Research Center.
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.Resource Links
